Cardiovascular Disease Doctors in Montrose, CO Accepting Medicare

8 Cardiovascular Disease doctors found. Showing 1 - 8

Luther Basel Weathers Iii, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 630 E Star Ct, Montrose, CO 81401 Phone: 970-252-1020    Fax: 970-252-1041

Charles Everett Wilkins, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 630 E Star Ct, Montrose, CO 81401 Phone: 970-252-1020    Fax: 970-252-1041

Bradley D Huhta, MD FACC Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 17 N Mesa Ave, Montrose, CO 81401 Phone: 970-252-1020    Fax: 970-252-1041

Paul A Becker, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 17 N Mesa, Montrose, CO 81401 Phone: 970-252-1020    Fax: 970-252-1041

Dr. David Sukmin Lee, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 630 E Star Ct, Montrose, CO 81401 Phone: 970-252-1020    Fax: 970-252-1041

Mojgan Arashvand, DO Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 630 E Star Ct, Montrose, CO 81401 Phone: 970-252-1020    Fax: 970-252-1041

Dr. Gregory D Ross, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 630 E Star Ct, Montrose, CO 81401 Phone: 970-252-1020

Dr. Riley D. Foreman, DO Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 630 E Star Ct, Montrose, CO 81401 Phone: 970-252-1020    Fax: 970-252-1041

News Archive

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

A.D.A.M. announces Q2 financials

A.D.A.M., Inc. (Nasdaq: ADAM), a leading provider of health information and benefit technology solutions, announced financial results for the second quarter ended June 30, 2009.

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

Sir Michael Stratton, Thijn Brummelkamp and Anne Glover to speak at The EMBO Meeting 2013

Predisposition to cancer and other diseases, genetic testing, infectious proteins and ubiquitin signalling - these are some of the topics internationally renowned speakers will tackle at The EMBO Meeting 2013 to be held in Amsterdam, the Netherlands, from 21-24 September 2013.

Read more Medical News

› Verified 8 days ago